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Background: Estrogens have an important role in determining immune system 
development, regulation and response to stimuli. Estrogens also influence 
pathogenesis and progression of autoimmune diseases, including Systemic Lupus 
Erythematosus (SLE), where there is a strong sex bias: female to male prevalence 
ratio is about 9:1. Estrogens, and in particular 17-β estradiol (E2), act as 
transcription factor through the binding to its specific receptors, ERα and ERβ.  
Among genes regulated by E2,  Interferon α (IFNα) and B Lymphocyte Stimulator 
(BLyS) seem to be affected, and BLyS seems to be an IFN-inducible gene. Both 
cytokines are increased in SLE patients, indicating a link between hormones and 
cytokines induction in autoimmunity; BLyS over-expression can represent also a 
sign of the so called “IFN signature” characterizing systemic autoimmune 
diseases. 
Objective: The aim of the present study was to evaluate the effects of E2 on BLyS 
mRNA and protein expression in a human myeloid cell line, in order to propose 
an in vitro model of estrogen systemic immunomodulation, also considering IFNα 
as a possible mediator of this signaling pathway. 
Materials and Methods: U937 monocytes and U937-derived macrophages (treated 
with 50ng/mL Phorbol 12-Myristate 13-Acetate for 72 hours, Sigma-Aldrich) 
were exposed to E2 (Sigma-Aldrich) 100nM, 10nM, 1nM or 0.1nM. Cell viability 
was evaluated with Trypan Blue and Burker Chamber cell counting. Total RNA 
was extracted after 6, 24 and 48 hour administration, and culture medium was 
collected for protein quantification. Quantitative PCR was performed for BLyS 
and IFNα genes. GAPDH was used as reference gene. Primer concentration was 
100nM and cDNA quantity was 25ng. Data were analyzed with 2
-ΔΔCt
 method and 
statistical analysis was performed with REST-384© version 2 using Pair Wise 
Fixed Reallocation Randomisation Test©. ELISA assay, using a commercially 
available kit “Quantikine® ELISA” for Human BAFF/BLyS/TNFSF13B (R&D 
System) was performed for BLyS protein detection in culture supernatants. Data 
were normalized for total protein and differences in protein levels between treated 
and control cells during times were performed with multivariate analysis for 
repeated measures. The same protocols were used for treatment with exogenous 
human recombinant INF (hr-IFNα, 1000IU/mL, Enzo Life Sciences), 
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investigating BLyS mRNA expression at 6, 10, 24 and 48 hour and BLyS protein 
release at 6, 24 and 48 hour administration. 
Results: E2 did not induce any modulation of BLyS gene expression at any time or 
concentration used, in both monocytes and derived-macrophages. BLyS protein 
release was increased during time, and the highest E2 doses induced BLyS protein 
mobilization in monocytes, while a BLyS release was noticed in derived-
macrophages starting from 1nM E2. In monocytes, E2 induced a time-dependent 
IFNα up-regulation especially at doses 10nM and 1nM, while in differentiated 
macrophages E2 induced a significant IFNα down-regulation at 24 hours at doses 
100nM and 10nM. IFNα treatment induced a significant up-regulation of BLyS, 
both in monocytes and in derived-macrophages at any time of treatment, but the 
effect was higher and faster in differentiated cells than in steady-state monocytes. 
Regarding BLyS protein release, IFNα treatment did not induce a significant 
BLyS increase compared with that observed in untreated cells. 
Conclusion: Within 48-hour treatment E2 dose-dependently induces IFNα, but not 
BLyS expression, while exogenous IFNα affects BLyS transcription but not protein 
release. These findings suggest that estrogens could primarily have a role in the 
modulation of cytokines belonging to innate immunity, such as IFN, with 
different effects depending on target cell phenotype and milieu. Estrogen 
modulation of adaptive immune response, here exemplified by BLyS, seems to be 
the result of estrogen-induced IFN up-regulation, thus confirming the link 
between innate and adaptive immune activation in systemic autoimmunity. 
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Background: Gli estrogeni svolgono un ruolo importante nel determinare lo 
sviluppo, la regolazione e la risposta agli stimoli del sistema immunitario. Essi 
sono implicati anche nella patogenesi e nella progressione delle malattie 
autoimmuni, come il Lupus Eritematoso Sistemico (LES), dove la prevalenza 
delle donne sugli uomini risulta essere di 9 a 1. Gli estrogeni, ed in particolare il 
17-β estradiolo (E2), agiscono come fattori di trascrizione attraverso il legame con 
i loro specifici recettori, ERα ed ERβ. Tra i geni regolati da E2 troviamo 
l’Interferone α (IFNα) e B Lymphocyte Stimulator (BLyS); BLyS sembra essere 
un gene indotto anche da IFNα. Entrambe queste citochine si trovano ad alti livelli 
nei sieri dei pazienti con LES, indicando un possibile collegamento tra ormoni e 
induzione citochinica nell’autoimmunità; l’over-espressione di BLyS può anche 
rappresentare un segnale della cosiddetta “IFN signature”, che caratterizza le 
malattie autoimmuni sistemiche. 
Obiettivo: Lo scopo del presente studio è stato quello di valutare gli effetti di E2 
sull’espressione di BLyS mRNA e proteina in una linea cellulare mieloide umana, 
così da proporre un modello in vitro di immunomodulazione sistemica indotta da 
estrogeni, considerando IFNα come un possibile mediatore di questa via di 
segnale. 
Materiali e Metodi: Cellule umane U937, monocitarie e simil-macrofagiche 
(trattati con 50ng/mL di Forbolo 12-Miristato 13-Acetato, Sigma-Aldrich), sono 
state trattate con E2 (Sigma-Aldrich) alle concentrazioni 100nM, 10nM, 1nM, 
0.1nM. La vitalità cellulare è stata valutata mediante conta cellulare con il 
colorante vitale Trypan Blue e Camera di Burker. L’RNA totale è stato estratto 
dopo 6, 24 e 48 ore dal trattamento, e il medium di coltura è stato raccolto per la 
quantificazione proteica. La PCR quantitativa (qPCR) è stata eseguita per i geni 
BLyS e IFNα. GAPDH è stato utilizzato come gene reference. Sono stati utilizzati 
i primer alla concentrazione 100nM e cDNA nella quantità di 25ng. I dati sono 
stati analizzati con il metodo 2
-ΔΔCt e l’analisi statistica è stata eseguita con REST-
384© version 2 using Pair Wise Fixed Reallocation Randomisation Test©. Per 
determinare la quantità di proteine nel surnatante di coltura è stato utilizzato il kit 
ELISA commerciale “Quantikine® ELISA” for Human BAFF/BLyS/TNFSF13B 
(R&D System). I livelli di BLyS proteina sono stati normalizzati per i livelli di 
proteine totali e le differenze nei livelli di proteina tra cellule trattate e di controllo 
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sono stati valutati con un’analisi multivariata per misure ripetute. Gli stessi 
protocolli sono stati utilizzati per il trattamento con IFNα ricombinante umano 
esogeno (hr-IFNα, 1000IU/mL, Enzo Life Sciences), indagando l’espressione 
dell’mRNA di BLyS a 6, 10, 24 e 48 ore e il rilascio di BLyS proteina a 6, 24 e 48 
ore dal trattamento. 
Risultati: E2 non induce modulazione dell’espressione genica di BLyS ai tempi e 
alle concentrazioni testate, sia nei monociti che nei macrofagi-derivati. I livelli di 
BLyS proteina nel surnatante di coltura aumentano nel tempo, le più alte dosi di 
E2 inducono la mobilizzazione e il rilascio di BLyS in coltura nei monociti, 
mentre nei macrofagi-derivati si è notato un rilascio di BLyS partendo dalla 
concentrazione di E2 1nM. Nei monociti E2 induce un’up-regolazione tempo-
dipendente di IFNα, specialmente alle dosi 10nM e 1nM, mentre nei macrofagi 
differenziati E2 induce una significativa down-regolazione di IFNα a 24 ore, alle 
dosi 100nM e 10nM. Il trattamento con IFNα induce una significativa up-
regolazione di BLyS, sia nei monociti che nei macrofagi-derivati ad ogni tempo di 
trattamento, ma gli effetti sono risultati più rapidi e più marcati nei macrofagi 
rispetto ai monociti. Per quanto riguarda il rilascio di BLyS proteina, il 
trattamento con IFNα non ha indotto un significativo aumento di BLyS rispetto 
alle cellule non trattate. 
Conclusioni: Entro 48 ore, il trattamento con E2 modifica in maniera dose-
dipendente l’espressione di IFNα, ma non quella di BLyS, mentre IFNα esogeno 
influisce sulla trascrizione di BLyS, ma non sul rilascio della proteina stessa. 
Queste evidenze suggeriscono che gli estrogeni possono avere primariamente un 
ruolo nella modulazione di citochine appartenenti all’immunità innata, come 
l’IFNα, con effetti differenti dipendenti dal fenotipo cellulare e dal milieu 
citochinico. La modulazione estrogenica della risposta immunitaria adattativa, qui 
esemplificata da BLyS, sembra essere il risultato dell’up-regolazione di IFNα 
indotta da estrogeni, a conferma della stretta inter-relazione tra immunità innata e 
adattativa nell’autoimmunità sistemica. 
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1.1 Estrogens and systemic autoimmune diseases 
Immunity is the balanced state of our immune system that realizes 
adequate biological defenses and responses against pathogens and non-self 
particles. Immune system has specific properties in order to induce 
protection: recognition, specificity, production of antibodies, cell-mediated 
reaction and memory. When there is a breakdown in this balance, immune 
system can undergo different pathological states: 
 Autoimmunity: inability to discriminate between self and non-self 
 Immunodeficiency: absent/inadequate immune response 
 Hypersensitivity: extreme/inappropriate immune response 
In immunity and pathological immune conditions, sex differences play an 
important role in determining immune system development, regulation and 
response to stimuli. In particular, females are more resistant to infections than 
males, because of their heightened immune response, but at the same time 
they are more prone to develop autoimmune disorders and inflammatory 
diseases [1]. Sex hormones are key effectors of sexual dimorphism in 
immunity and autoimmunity: in Systemic Lupus Erythematosus (SLE), the 
prototype systemic autoimmune disease, female to male prevalence ratio is 
around 9:1 [2]. Estrogens are female sex hormones deeply involved in 
development, progression and maintenance of autoimmune diseases, 
including SLE. 
1.1.1 Estrogens 
Estrogens are primarily produced by ovaries and to a lesser extent by 
adrenal gland and testis. Estrogens, like other steroid hormones, originate by 
cholesterol through the so called steroidogenesis. The biosynthesis of steroids 
is mediated by enzymes. Estrogens derived from steroidogenesis are: 
estradiol, estrone and estriol. 17-β estradiol (E2), primarily produced by 
ovaries, is the major estrogenic metabolite. E2 derives from testosterone 
through the action of the enzyme aromatase (Figure 1.1). Due to their 
hydrophobic nature, all steroids circulate in blood system complexed to 
proteins, aspecific (albumin) or specific ones. Circulating E2 binds sex 
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hormones binding globulin (SHGB) with high affinity, and albumin with low 
affinity. Estrogen concentrations vary during different physiological states in 
women, ranging from 0-30pg/mL during menopause to 188-7192pg/mL 
during  pregnancy. 
 
Figure 1.1 Estrogen biosynthesis 
[http://chemistry.gravitywaves.com/CHE452/23_Sex%20Steroid%20Horm.htm] 
Estrogens perform their activity through the binding to specific receptors. 
Estrogen receptors (ERs) are dimetric nuclear receptors, which are inhibited 
by heat shock proteins (Hsp) binding: when estrogens bind receptors, Hsp is 
unbound and the complex estrogen-receptor acts as a transcription factor for 
estrogen specific target genes (Figure 1.2). 
 
 
Figure 1.2: Estrogen receptor structure 
[http://farmacia.unich.it/fisiologia/didattica/fisioc/lez/AA_2010-
11/complementi/complementi_di_fisiologia_del_28-marzo-5aprile-2011.pdf] 
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Gene expression regulation by E2 and ER is a multifactorial process, 
involving both genomic and non genomic actions. The genomic pathway is 
activated by the direct binding of E2-ER to estrogen responsive elements 
(ERE) on the target gene’s promoter, or by the interaction of E2-ER with 
other transcription factors (like AP-1 or SP-1), that indirectly bind promoter 
regions. The non genomic pathway has a rapid effect, because E2 binds 
membrane ERs, activates kinases and phosphatases and increases the ion flux 
across the membranes, causing physiological effects. The last pathway is the 
ligand-indipendent one, where growth factor signaling leads to activation of 
kinases that may phosphorylate and activate transcription factor activity of 
ERs [3] (Figure 1.3). 
 
Figure 1.3: Models of pathways involved in ERs activation [3]. 
ERs possess highly conserved functional domains: the central and most 
conserved one, the DNA-binding domain (DBD), is involved in DNA 
recognition and binding, whereas the ligand-binding domain (LBD) is the 
COOH-terminal multifunctional region. At the NH2-terminus, there is the 
transcription-activating function 1 (AF-1) domain, at the COOH-terminus 
LBD, there is the transcription-activating function 2 (AF-2) domain. Both AF 
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domains recruit a range of co-regulatory protein complexes to the DNA-
bound receptor [3] (Figure 1.2 and Figure 1.4). There are two distinct 
estrogen receptors, ERα (NR3A1) and ERβ (NR3A2), both belonging to the 
nuclear receptor (NR) family of transcription factors and with high sequence 
affinity (Figure 1.4). They are encoded by different genes located on 
chromosome 6 (6q25.1) and chromosome 14 (14q22-24), respectively. They 
have different tissue distribution, transcriptional effect and ligand-binding 
affinity. ERα, when activated, promotes cellular proliferation and 
differentiation pathways, while ERβ seems to act as a transcription repressor, 
promoting an anti-proliferative effect. 
 
 
 
 
 
E2 could use different signaling pathways depending both on the cellular 
type and on the physiological status of the cell. In this way, E2 evokes 
distinct gene responses in different types of target cells. 
1.1.2 Estrogens and Systemic Lupus Erythematosus 
SLE is a systemic autoimmune disease, in which pathogenesis is complex, 
multifactorial, and not fully understood. Both genetic and environmental 
factors are involved, and autoantibody production and immune-complex 
deposition are key effector factors. SLE primarily affects females of 
childbearing age, with a female:male ratio of about 9:1 [2], suggesting a role 
for sex hormones in disease pathogenesis. Fluctuations of endogenous 
estrogens’ concentrations, corresponds to fluctuations in the disease activity: 
on this regard, pregnancy represents a good physiological model in which a 
T-helper 2 (Th2)-guided humoral immune response is established, and high 
estrogen levels could be responsible for Th1-Th2 shift [4]. In SLE, humoral 
Figure 1.4 Estrogen receptor isoforms: ERα and ERβ 
[https://en.wikipedia.org/wiki/Estrogen_receptor] 
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immune response is aberrantly activated, and pregnancy state could induce a 
flare of the disease [5]. Also hormonal replacement therapy (HRT) and the 
use of oral contraceptives are linked to an increased risk of SLE, indicating 
that also exogenous estrogens could affect lupus disease activity [6,7]. SLE 
patients also show an altered steroid hormone metabolism, leading to an 
increased concentration of estrogen metabolites in plasma [8]. Studies on 
animal models confirm the role of  estrogens in promoting the development 
of SLE. New Zeland Black/White F1 (NZB/W F1) mice is a lupus-prone 
murine model that spontaneously develops glomerulonephritis (GLN) within 
20-28 weeks of age [9]. Ovariectomy [10] or genetic ablation of ERα 
signaling [11] in this mouse model, showed decreased autoantibody 
production and mortality, while 17-β estradiol treatment accelerates GLN and 
disease progression [12]. Regarding these evidences, both endogenous and 
exogenous estrogens could modulate disease activity, probably via ERα 
activation: another study in NZB/W F1 mice has demonstrated that ERα 
activation exerts an immune-stimulatory effect in lupus, while ERβ activation 
has a poor immunosuppressive effect on the disease [11,13]. ERs are present 
in specific immunocompetent cells: monocytes-macrophages, and T and B 
cells [8]. Usually, estrogens enhance cell proliferation and reduce cell 
apoptosis [14], but it was also demonstrated that high doses (10
-4
M – 10-7M), 
similar to those achieved during pregnancy, induce cell cycle arrest and 
apoptosis in monocyte cell lines [15]. This evidence suggests the role of 
estrogens in pregnancy in reducing cell-mediate immune response, thus 
favoring humoral response. Concerning cells of the adaptive immune system, 
estrogens can alter survival and activation of B cells in a B cell-autonomous 
fashion, inducing auto-reactivity and proliferation [16]; moreover, estrogens 
promote survival of self-reactive B cells at peripheral check-point, evading 
immune tolerance mechanism, being this a fundamental step in autoimmunity 
development [17]. Self-reactive B cells can survive also by the increased 
production, by myeloid cells, of the B-cell survival factor tumor necrosis 
factor ligand superfamily member 13B (TNFSF13B), also known as B 
Lymphocyte Stimulator (BLyS) or B-cell activating factor (BAFF), which 
seems to be stimulated by E2 [12,18]. Estrogens can also modulate the 
16 
 
production of pathogenic IgG autoantibodies, influencing IgG subclass 
selection [19,20]. A recent study demonstrated that ERs bind directly to key 
regulatory elements in the immunoglobulin heavy chain locus in activated B 
cells, influencing antibody expression and class switching recombination, 
thus altering B cell responses to self- and non-self-antigens [21]. So, 
estrogens can affect autoantibodies repertoire, influencing both the risk and 
the severity of the disease. In autoimmune disorders autoantibodies bind 
autoantigens, derived mainly from impaired clearance of apoptotic debris, 
forming immune-complexes (ICs) that can deposit in specific organ tissues 
(i.e. the kidney). Autoimmunity can be promoted also by an imbalance in 
different subsets of CD4
+
 cells. Estrogens reduce the number of immature 
thymic lymphocytes (CD4
+
/CD8
+
) and thymic stromal tissue, through thymic 
involution, thereby interfering with T-negative selection and tolerance 
induction, while enhancing hepatic T cell lymphopoiesis [22,23]. The 
production of auto-reactive T helper cells is involved in the breakdown of B 
cell self-tolerance, inducing production of autoantibodies, favoring the 
development of autoimmunity [24,25]. Estrogens can regulate pathways 
leading to the production of Interleukin-2 (IL-2), an important determinant 
for T-cell tolerance and differentiation [26]. Moreover, timing and dose of 
estrogen influence T cell response: a continuous treatment of low-dose E2 
enhances antigenic-specific CD4
+
 T cell responses and strongly promotes 
Th1 cell development, with production of IFNγ (an important inducer of Ig-
class switching in B cells), and this effect requires the expression of ERα in 
hematopoietic cells [27]. Despite this last finding, pregnancy induces a shift 
from Th1 to Th2 humoral response, due to the higher levels of hormones, and 
in particular estrogens: this Th1-Th2 shift could explain why Th2-mediated 
autoimmune disease, such as SLE, tends to develop and worsen during 
pregnancy [28]. Estrogens can influence also CD4
+
 regulatory T (Treg) cells 
development and function, fundamental cells that prevent autoimmunity, 
controlling self-reactive B and T cells at the periphery [29]. In pregnant mice, 
expansion of maternal Treg populations specific for fetal antigens helps to 
protect developing fetuses against immune attack [30]. Major estrogen 
immunomodulatory effects are depicted in Figure 1.5. 
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An important cytokine, highly expresses in SLE patients, and strongly 
enhanced by estrogens, is type I Interferon (IFN). 
 
Figure 1.5: Potential mechanisms through which estrogen might modulate the loss of 
tolerance and regulate the production of pathogenic IgG autoantibodies in SLE. Modified 
from [31]. 
 
1.2 Type I Interferon system 
1.2.1 Type I Interferon in SLE 
Interferons (IFNs) are a group of cytokines, produced and released by host 
cells in response to the presence of pathogens or tumor cells. IFNs are so 
named for their ability to “interfere” with viral replication, protecting cells 
from virus infection. IFNs are typically divided into three different groups: 
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type I, type II and type III IFNs. The type I IFN family is the largest one and 
has a pivotal role in SLE pathogenesis: it includes 12 different IFNα 
subtypes, and one IFNβ, IFNω, IFNε and IFNκ subtype each [32]. Type I 
IFNs are produced by all leucocytes, but the most potent producer is the 
plasmacytoid dendritic cell (pDC). Pattern recognition receptors (PRRs), 
including Toll Like Receptors (TLRs), localize in the cytosol or in the 
endosome of different immune cells, and recognize viruses, bacteria or 
microbial nucleic acids, inducing the pathway of IFN production. In 
particular TLRs recognize double stranded (ds)RNA (TLR3), single stranded 
(ss)RNA (TLR7) or dsDNA (TLR8 and TLR9) [33]. All type I IFNs bind the 
ubiquitously expressed heterodimeric IFNα/β receptor (IFNAR), activating 
the canonical signaling pathway JAK/STAT. The transcription factor 
complex STAT1-STAT2-IRF9 formed, binds interferon-stimulated response 
elements (ISREs) in promoters of IFN-regulated genes, and induces the 
transcription of genes that act in  preventing virus replication and expansion 
(antiviral properties) (Figure 1.6) [34].  
 
Figure 1.6: Canonical JAK/STAT signaling pathway of type I IFNs [35]. 
Type I IFNs modulate also the innate and the adaptive immune system, in 
order to induce an efficient clearance of viruses and develop a long-lasting 
immunity. Type I IFNs enhance maturation, activation and chemokine release 
by cells of innate immunity, modulate the polarization and the differentiation 
of T cells, and activate B cells, increasing TLR7 and TLR9 expression on 
their surface and BLyS production, and inducing differentiation into 
antibody-producing plasma cells [36]. An autoimmune disease can occur 
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when there is an inappropriate regulation of type I IFN system, leading to a 
loss of peripheral tolerance. Evidences indicate that IFNα administration in 
genetically predisposed patients, can cause an increase occurrence of 
autoantibodies and autoimmune diseases [37] and can worsen the disease 
[38]. SLE patients present increased serum levels of type I IFNs: ICs, 
containing nucleic acids derived by impaired clearance of apoptotic or 
necrotic cells [39,40], could act as endogenous inducers of IFNs, activating 
DCs through TLR7 or TLR9 [41,42]. Evidences in pediatric lupus patients 
[43], suggest the role of type I IFN system in initiating the disease process. 
Studies in murine models confirm the role of IFNα in exacerbating GLN, 
augmenting BLyS production and reducing survival in NZB/W F1 mice 
compared to wild-type mice [44]; the inhibition of both TLR7 and TLR9 in 
the same lupus mouse model, leads to the improvement of proteinuria, GLN 
and reduction of autoantibody production and amelioration of the disease 
[45], indicating an important role for TLR in inducing type I IFN pathway in 
SLE. An etiopathogenic model of SLE could include an initial infection by a 
virus that induces type I IFN production and release of cellular material from 
dying cells. Impaired clearance of apoptotic cells is a source of autoantigens: 
self-nucleic acids are recognized by TLRs, present on the surface of DCs, that 
internalize them and start the production of IFNα, stimulating their 
maturation and autoantigen presentation. B and T cells are recruited by DCs 
and B lymphocytes are activated to produce autoantibodies [46]. TLRs, 
present on the surface of auto-reactive B cells, can co-stimulate B cells, 
together with autoantigens, and can lead to the activation and differentiation 
into antibody-producing plasma cells [47]. Nucleic acids binding 
autoantibodies form ICs that can be internalized by plasmacytoid DCs 
(pDCs), producing IFNα, which stimulates and activates DCs and T cells, 
leading to the chronic activation of type I IFN and the self perpetuation of 
antibody production and inflammation [48] (Figure 1.7).  
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Type I IFN production is controlled by a network of cytokines, surface 
receptors and immune cells, but also hormones have an important role in IFN 
modulation. 
1.2.2 Estrogen and type I IFN in SLE 
Estrogen enhances type I IFN production, inducing a sexual dimorphic 
response: women produce a stronger type I IFN response than men, when 
vaccinated [50] or when pDCs are activated [51]. E2 administration, through 
ERα activation, seems to stimulate IFNα production by pDCs of post-
menopausal women, stimulated ex vivo with SLE-related immune complexes 
[52]. Experiments on mouse models demonstrate that the increased 
production of IFNα by pDCs via ERα, mediates up-regulation of genes 
involved in type I IFN production; such gene over-expression induces the 
development of autoimmune kidney disease via IFNα activation. IFNα can 
also produce a feed-forward loop, inducing expression of ERα, amplifying E2 
signaling in innate immune cells [31] (Figure 1.5). A recent study 
Figure 1.7: Model of innate immune responses in autoimmunity [49]. 
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demonstrates that also environmental estrogen, bisphenol A (BPA), 
stimulates type I IFN signaling, through the up-regulation of both ERα and 
IFNs in murine and human myeloid cells, augmenting IFN-inducible proteins 
that regulate innate immune responses (activating inflammasome activity) 
and modifying lupus susceptibility [53]. As in innate immune cells, ER 
activity may regulate also the function of adaptive immune cells. A recent 
study highlighted the role of E2 in inducing IFNα activation in B cells: E2 via 
ERα down-regulates the expression of microRNA (miRNA), promoting IKKε 
expression that phosphorylate STAT1, inducing the transcription of IFNα 
inducible genes, affecting B cell activity [54] (Figure 1.8). 
 
Figure 1.8: Proposed effective mechanism of E2 on amplifying IFNα signaling activation in 
B cells [54]. 
 
1.3 B Lymphocyte Stimulator (BLyS) 
1.3.1 BLyS and SLE 
B lymphocyte stimulator (BLyS), also known as B cell-activating factor 
(BAFF) or tumor necrosis factor ligand superfamily member 13B 
(TNFSF13B) was discovered in 1999 [55], and more recently, it was 
identified as a key cytokine in SLE pathogenesis [56]. BLyS is a type II 
membrane protein member of the TNF family, highly conserved during 
evolution; its gene is located on chromosome 13q34 and encodes a protein of 
285 aminoacids [57]. Membrane BLyS can be cleaved at a furin protease site, 
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obtaining the soluble cytokine [55,57]; evidences in neutrophils suggest that 
cells can also produce and store soluble BLyS and release it under specific 
stimuli [58,59]. BLyS is mainly produced by primary myeloid cells 
(macrophages, neutrophils and DCs), and also produced by myeloid cell lines, 
such as K-562, HL-60, THP-1 and U937 [57]. BLyS can be bound by three 
receptors: TNF receptor superfamily member 13C (BAFF receptor [BAFF-R] 
or BLyS receptor 3 [BR3]), TNF receptor superfamily member 17 (B-cell 
maturation antigen [BCMA]) and TNF receptor superfamily member 13B 
(transmembrane activator and cyclophilin ligand interactor [TACI]). BCMA 
and TACI can bind also a proliferation-inducing ligand (APRIL), a related 
cytokine member of the TNF superfamily member, while BR3 specifically 
recognizes BLyS [60]. BR3 and TACI are expressed on B cells, while BCMA 
is expressed on plasmablasts and plasma cells: BLyS-BR3 binding promotes 
survival and maturation of immature B cells, BLyS-TACI binding induces T-
cell-independent responses of B cells to type I and type II antigens, negative 
regulation of B-cell compartment and class-switch recombination of B cells, 
BLyS-BCMA binding promotes plasma cell survival [61] (Figure 1.9). BLyS-
mediated B-cell maturation consists into two steps: at first, soluble BLyS 
binds BR3 on B cells, promoting B-cell survival; at second, membrane BLyS-
TACI binding modulates B-cell phenotype [62]. 
 
Figure 1.9: Soluble BAFF and APRIL signaling. Modified from [61]. 
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BLyS exerts fundamental roles in maturation, survival and differentiation 
of B cells: BLyS promotes B cell maturation in the spleen at the T1-T2 
immune tolerance check-point [63], and its excess may lead to expansion of 
low-affinity self-reactive B cells, mainly marginal zone (MZ) B cells [64]. 
BLyS exerts a regulatory effect also on T cell function [65,66]. BLyS over-
expression in mice (BLyS transgenic mice), can induce an impaired 
production of mature B cells as well as effector T cells, and consequently 
autoantibodies, leading to the development of an autoimmune disease, similar 
to human SLE [67,68], while BLyS blockade reduces SLE flares in mouse 
models [69] and BLyS knock-out mice become immunodeficient [70]. 
Evidences of BLyS-substained autoimmunity in mouse models are 
strengthened by the observation that BLyS serum levels are higher in SLE 
patients than in healthy individuals and correlate with disease activity, 
modifying the threshold for negative selection and favoring the survival of 
auto-reactive B cells [71,72]. All these findings suggest BLyS as an effective 
target for the treatment of SLE. Belimumab is the first biological target 
therapy approved for SLE treatment: it is a fully human recombinant 
monoclonal IgG1λ antibody, which targets soluble human BLyS [73]. 
1.3.2 Estrogen and BLyS in SLE 
As previously mentioned, estrogen induces BLyS expression and 
production: a recent study from our group in NZB/W F1 lupus-prone mice 
suggests the effect of exogenous estrogen in inducing BLyS release and 
disease exacerbation: the direct correlation found between BLyS and anti-C1q 
or anti-dsDNA production indicates that BLyS over-production influences 
self-B cell repertoire, increasing levels of nephritogenic autoantibodies  [12]. 
In addition, a model of BLyS up-regulation by E2 and IFNα in primary 
myeloid murine cells has been described [18]. Studies performed in primary 
human myeloid cells confirm the role of type I IFN in inducing SLE disease, 
also through the up-regulation of BLyS: IFNα influences the mobilization 
from intra- to extracellular compartments of BLyS in primary human 
monocytes and this mechanism is accelerated more in myeloid cells of active 
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SLE patients than in cells of healthy people [74]. These evidences suggest 
BLyS as an E2- and an IFN-inducible gene (Figure 1.10). 
 
Figure 1.10: Role of BLyS in the pathogenesis of SLE [61]. 
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AIM OF THE STUDY 
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Sex dimorphism is strictly related to the pathogenesis of systemic autoimmune 
diseases, including Systemic Lupus Erythematosus (SLE). In this context 
hormones, and estrogens in particular, play an important role in molecular 
mechanisms sustaining autoimmunity. Recent in vivo studies in lupus-prone mice, 
highlighted the role of 17-β estradiol in the modulation of cytokines, including B 
Lymphocyte Stimulator (BLyS). BLyS is produced by myeloid cells and affects 
maturation and survival of B cells. Its over-expression in SLE patients suggests its 
pivotal role in SLE pathogenesis and progression. Despite evidences, the 
molecular mechanisms leading to autoimmunity by estrogen and BLyS interaction 
remain poorly understood, also because results from ex vivo studies in humans are 
inconsistent, heterogeneous and scarcely reproducible. Monocyte/macrophage 
cells are implicated in initiation, maintenance and resolution of inflammatory 
response through signal molecules, which can also affect adaptive immune cell 
functions. U937 is a human myeloid cell line that can respond to estrogen 
signaling and constitutively expresses BLyS. 
The aim of the present study was to evaluate the effects of 17-β estradiol on 
BLyS mRNA and protein expression in a human myeloid cell line, in order to 
propose an in vitro model of estrogen systemic immunomodulation, also 
considering IFNα as a possible mediator in this signaling pathway. 
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MATERIALS AND METHODS 
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2.1 Reagents 
2.1.1 Phorbol 12-Myristate 13-Acetate 
Phorbol 12-Myristate 13-Acetate (PMA) (Sigma-Aldrich, Saint Louis, 
MO, United States) was diluted in Dimethyl Sulfoxide (DMSO) (Sigma-
Aldrich) to the final concentration of 12.5mg/mL (20mM). Stock solution 
was maintained at -80°C. Further dilutions with DMSO were performed to 
obtain a final working concentration of 50µg/mL (80µM). Aliquots of diluted 
solution were maintained at -20°C. 
2.1.2 Estrogen 
17-β estradiol (E2) (Sigma-Aldrich) was diluted in sterile Absolute 
Ethanol Anhydrous (EtOH) (Carlo Erba Reagents, Milan, Italy) to the final 
concentration of 1mM. Work aliquots of stock solution were maintained at -
20°C in glass vials, protected from light, as indicated in manufacturer’s 
instruction. Dilutions from stock solution were performed with culture 
medium just before cell culture treatment. 
2.1.3 Interferon α 
Human recombinant Interferon α-2b (hr-IFNα) (Enzo Life Sciences, 
Farmingdale, NYC, USA) was reconstituted with sterile distilled water to the 
final concentration of 0.1mg/mL, corresponding to a total activity of 
500∙103IU/mL. Stock solution was maintained in aliquots at -80°C. 
 
2.2 Human myeloid cell line 
U937 is a monocytic cell line derived from 37 years old man with a 
histiocytic lymphoma. Cells grow in suspension and present a big round 
shape with cytoplasmatic inclusions visible at the phase contrast microscope 
Telaval 31 (Zeiss, Oberkochen, Germany) (Figure 2.1). U937 cell line was 
used for all experiments. Cells were maintained in Roswell Park Memorial 
Institute medium (RPMI 1640) (Life Technologies, Carlsbad, CA, USA) 
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supplemented with 10% Fetal Bovine Serum (FBS) (Life Technologies), 1% 
Penicillin/Streptavidin (100µg/mL) (Life Technologies) and 1% Glutamine 
(200mM) (Life Technologies). U937 cells were cultured in vertical 75cm
2
 
flasks (Corning Incorporated, BD Falcon
TM
, Corning, NY, USA) at 37°C 
under normoxia (air plus 5% CO2) in a humidified atmosphere (Incubator 
CO2 Model Series 6000, Heraeus Instruments, Hanau, Germany). Medium 
was changed every 3-4 days to maintain cell density from 100.000cells/mL 
up to 1.000.000cells/mL. Cell count, to define cell density, was performed 
using Burker chamber and Trypan Blue vital staining (Sigma-Aldrich). 
 
Figure 2.1:U937 cells at phase contrast microscope. Magnification 200x. 
2.2.1 U937 PMA differentiation 
U937 cells were induced to differentiate in macrophage-like cells using 
PMA. Several cell densities, PMA concentrations and times of treatment were 
tested. Cell differentiation was evaluated for cell adhesiveness, presence of 
pseudopodia and increased cell dimensions. 1.000.000 cells treated with 
50ng/mL PMA after 72 hours at dark, showed marked adhesiveness to the 
plate, formed cell-aggregates (Figure 2.2A), augmented dimensions and 
presented pseudopodia (Figure 2.2B). 
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2.3 In vitro treatment protocols 
2.3.1 Estrogen 
U937 cells were seeded at 500.000cells/mL in 12-wells plate. E2 was 
added at different concentrations: 100nM, 10nM, 1nM, 0.1nM. EtOH (E2 
vehicle) was added in control wells, to reach a final concentration of 0.01%. 
In U937 derived-macrophages, medium containing PMA was replaced with 
medium containing E2 or EtOH. Cells were harvested after 6, 24 and 48 
hours. Three independent experiments, for each cell line, were performed. 
2.3.2 IFNα 
U937 cells were seeded at 500.000cells/mL in 12-wells plate. hr-IFNα was 
added at the final concentration of 1000IU/mL. In U937 derived-
macrophages, medium containing PMA was replaced with medium 
containing hr-IFNα or without treatment (control wells). Cells were harvested 
after 6, 10, 24 and 48 hours. Three independent experiments, for each cell 
line, were performed. 
 
Figure 2.2: U937-derived macrophages after PMA treatment at phase contrast microscope. A: 
cells aggregates derived from PMA differentiation. Magnification 100x. B: Cells with 
pseudopodia derived from PMA differentiation. Magnification 200x. 
B A 
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2.4 Real-time reverse transcription polymerase chain reaction 
2.4.1 RNA extraction 
Total RNA was isolated from cells using TRIzol
®
 Reagent (Life 
Technologies). U937 cells were harvested by centrifugation at 2000rpm 
(revolutions per minute) for 2 minutes and washed with 1mL sterile 
Phosphate-Buffered Saline (PBS). Growth medium was collected from each 
sample and stored at -80°C for protein quantification. Cell pellets were 
treated with 300µL TRIzol
®
 and incubated 5 minutes at room temperature 
(RT); chloroform (Sigma-Aldrich) was added in ratio 1:5 
chloroform:TRIzol
®
. Samples were shacked vigorously by hand for 15 
seconds and then incubated 5 minutes at RT. Samples were then centrifuged 
at 12000g for 15 minutes at 4°C. The aqueous phase, containing RNA (about 
50% of total volume), was removed and placed into a new tube. 1µL of 
glycogen (Life Technologies) and then 0.5mL 100% Isopropanol (Sigma-
Aldrich) per 1mL TRIzol
®
 used, were added. Samples were stored at -20°C 
for 30 minutes and then centrifuged 12000g for 20 minutes at 4°C. After 
centrifugation, RNA formed a gel-like pellet on the side and bottom of the 
tube. Supernatants were removed from the tubes with glass Pasteur pipette 
and RNA pellets were washed with 75% EtOH (ratio 1:1 ethanol:TRIzol
®
). 
Samples were centrifuged at 12000g for 10 minutes at 4°C and then EtOH 
was removed. RNA pellets were dried at air for about 5 minutes and then 
resuspended with DEPC treated water pyrogen free DNase/RNase free 
(Invitrogen, Carlsbad, CA, USA). 
For U937 derived-macrophages, RNA extraction protocol differentiated in 
cell harvesting. Growth medium was removed from culture wells, centrifuged 
to pellet suspension cells, and then placed in a new tube and stocked at -80°C 
for protein quantification. TRIzol
®
 reagent was added directly to wells, and 
adherent cells were lysed pipetting them up and down several times. 
Total RNA was quantified at Nanodrop 2000c Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA). RNA quantity starting from 
250ng/µL and with ratio 260/280 between 1,8 and 2, and ratio 260/230 near 
2, was considered a good sample for further experiments. 
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2.4.2 Retrotranscription 
RNA was retrotranscribed in cDNA (complementary DNA) using Reverse 
Transcription System Kit (Promega, Madison, WI, USA). 1µg RNA was 
incubated at 70°C for 10 minutes in thermo-block (Elettrofor, Rovigo, Italy); 
the sample was then briefly spun (13000rpm for 1 minute) and then placed on 
ice. Master mix reaction was prepared following this scheme: 
Reagents final concentration 
MgCl2, 25mM 5mM 
Buffer 10X 1X 
dNTP, 10mM 1mM each dNTP 
RNasin, 40u/µL 1u/µL 
Oligo(dT), 0.5µg/µL 0.5µg 
AMV Reverse Transcriptase, 25u/µL 0.75u/µL 
 
Mix was added to each sample, to reach the final volume of 20µL. Sample 
was incubated in 2720 Thermal Cycler (Applied Biosystem, Foster City, CA, 
USA) using the following program: 42°C for 15 minutes, 95°C for 5 minutes 
and 4°C for 5 minutes. cDNA samples, 50ng/µL concentrated, were stored at 
-20°C till used. 
2.4.3 Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
GoTaq
®
qPCR Master Mix (Promega) was used to perform qPCR for genes 
of interest. 
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Primer efficiency 
To determine the best cDNA quantity and primer concentration to be used 
both in U937 monocytes and in U937-derived macrophages, primer 
efficiency curve was performed. Scalar quantity of cDNA was tested (100ng, 
20ng, 4ng, 0.8ng and 0.16ng) with 100nM or 200nM primers. Threshold 
Cycle (Ct) obtained was interpolated on y-axis, while the log(base5) of cDNA 
quantity (5 because each cDNA quantity is 1/5 of the previous) was 
interpolated on x-axis. In the equation obtained (y=mx+q), the coefficient was 
used in the efficiency formula E=5
-(1/m)
. The percentage of efficiency was 
evaluated with this formula: E%=(1-E)∙100. E values between 1.95 and 2.05 
(95%-105%) were considered as good amplification efficiencies. 
Primer sequences were obtained from the software primer-BLAST by 
NCBI [http://www.ncbi.nlm.nih.gov/tools/primer-blast/]. Gene sequence was 
entered in the software and the following primer parameters included: PCR 
product size of 100-150 base pairs (bp), annealing temperature of 60°C (range 
from 57°C to 63°C) and spanning an exon-exon junction (to elude genomic 
contaminations). Because BLyS gene generates two transcripts, BLyS primers 
were created in order to include both mRNA isoforms. In the table below the 
primer sequences are reported: 
Gene Primer forward Primer reverse Melting 
Temperature 
GAPDH 5’-AAT GGA AAT CCC 
ATC ACC ATC T-3’ 
5’-CGC CCC ACT TGA 
TTT TGG-3’ 
78.5°C 
BLyS 5’-GAC TGA AAA TCT TTG 
AAC-3’ 
5’-TAT TTC TGC TGT 
TCT GAC-3’ 
78.0°C 
IFNα 5’-CCT GAT GAA TGC 
GGA CTC CA-3’ 
5’-TTC TGC TCT GAC 
AAC CTC CC-3’ 
80.5°C 
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Relative gene expression 
25ng cDNA was incubated with the following components: 
Components Initial Concentration Final Concentration 
GoTaq®qPCR Master Mix 2x 1x 
Primer F 10 µM or 20 µM 100 nM 
Primer R 10 µM or 20 µM 100 nM 
H2O To reach a final volume of 10 µL 
 
96-well plate with components and cDNA was sealed and it was 
centrifuged at 1100rpm for 1 minute to bring all reaction components together 
and eliminate air bubbles. qPCR reaction was performed with Real time PCR 
platform Bio-Rad CFX96 Real Time PCR Detection System (Bio-Rad, 
Hercules, CA, USA), following fast cycling program: 95°C for 2 minutes 
(first activation), 50 cycles of 95°C for 3 seconds (denaturation) and  62°C for 
30 seconds (annealing/extension). Dissociation/melting curve was obtained 
with 0.5°C increasing steps, each of 5 seconds, from 62°C to 95°C. The 
presence of a single pick in the melting curve indicated no contamination in 
samples and the presence of a single amplicon. Melting temperatures for each 
gene are indicated in the Table above. In each experimental plate also proper 
negative controls were added to exclude any contamination. Quantification of 
PCR products was normalized according to the amount of GAPDH cDNA 
(reference gene). Each sample for each experiment was loaded in triplicate. 
Relative quantification of gene expression was calculated by using a ΔΔCt 
(Ct, threshold cycle of real-time PCR) method based on signal intensity of the 
PCR, according to the following formula: ΔCt = Cttarget gene - CtGAPDH; ΔΔCt = 
ΔCttreatment - ΔCtcontrol; Ratio = 2
-ΔΔCt
 [75]. 
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2.5 Protein quantification 
2.5.1 Enzyme-linked immunosorbent assay (ELISA) for soluble human 
BLyS levels determination in culture supernatants 
Cell culture supernatants were tested for BLyS protein using a 
commercially available kit “Quantikine® ELISA” for Human 
BAFF/BLyS/TNFSF13B (R&D System, Minneapolis, MN, USA), following 
the manufacturer’s instructions. Optical densities (OD) were read at 450nm 
and 540nm (to correct value) at microplate reader Multiskan EX (Labsystems 
Diagnostics, Vantaa, Finland). Levels of BLyS were expressed as pg/mL; the 
range of detection was 4000pg/mL-62.5pg/mL and the sensitivity was 
2.68pg/mL. 
2.5.2 Bradford assay 
Total protein concentration in supernatants was quantified using the 
colorimetric Bradford’s protein assay [76]. Bradford colorant (Bio-Rad) was 
added to scalar dilutions of Bovine Serum Albumin (BSA), from 70.50µg to 
4.41µg, to create the standard curve. Optical Densities (OD) at 595nm of 
samples diluted in Bradford colorant, were read at DU
®
730, Life Science 
UV/Vis Spectrophotometer (Beckman Coulter, Brea, CA, USA). 
Concentrations were expressed as µg/µL. 
 
2.6 Statistical analyses 
Differences in cell densities between treated and control cells were 
determined using unpaired t-test (p<0.05 was considered as statistically 
significant). 
Statistical analyses for qPCR data were performed with Relative 
Expression Software Tool – 384 (REST-384©) version 2 using Pair Wise 
Fixed Reallocation Randomisation Test© [77]. Statistical significance was 
considered at p<0.01. 
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Differences in protein levels between treated and control cells during times 
were performed with multivariate analysis for repeated measures 
(ANCOVA), using IBM SPSS Statistics version 22.0 software. 
All graphs were designed with GraphPad Prism version 5 software. 
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RESULTS 
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3.1 U937 monocytes 
3.1.1 E2 treatment: cell growth 
U937 cell line was treated with different doses of E2 or EtOH at the 
highest concentration found in E2 administration (0.01%). Cells were counted 
after 24, 48 and 72 hours, in order to evaluate whether E2 (100nM) or EtOH 
could induce cell death or block cell proliferation. Figure 3.1 shows cell 
density at each time point in the three conditions: there is no significant 
difference in cell growth between untreated and EtOH- or E2-treated cells at 
each time point of observation. 
 
 
Figure 3.1: U937 cell density in untreated, EtOH-treated and E2-treated cells. Error bars 
represent standard deviations. 
EtOH treated cells were considered as controls in the following 
experiments. E2 at the highest dose did not affect cell proliferation and 
morphology: cells maintained round shape and cell inclusions. 
3.1.2 Primer efficiency curves 
Before evaluating target genes expression, primer’s efficiency was 
performed in U937 cell line. Table 3.1 indicates mean Ct values of GAPDH, 
BLyS and IFNα genes for each cDNA dilution (from 100ng to 0.16ng), using 
100nM primer concentration. LOG represents the log(base5) of cDNA serial 
dilution. Extreme values, that did not interpolate in a good way the curve, 
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were excluded. Figure 3.2 shows reference and target genes trends, with the 
corresponding linear regression equation and the coefficient of determination 
(R
2
). 
 
 
 
 
 
Table 3.1: Mean Ct values of GAPDH, BLyS and IFNα genes, at each cDNA dilution (from 
100ng to 0.16ng). Each sample was loaded in triplicate. St.Dev.=Standard Deviation. 
 
Figure 3.2: Efficiency curves of GAPDH (blue), BLyS (red) and IFNα (green) genes. For each 
gene the equation of linear regression is indicated. R
2
 = coefficient of determination. Ct = 
Threshold Cycle. LOG = log(base5) of cDNA quantity. 
Coefficient of determination values are near 1 and indicate that the line 
derived from points is similar to the line derived from linear regression. The 
efficiency for each gene is indicated in the expressions below. E is the 
efficiency, E% is the percentage of efficiency. 
 
GAPDH: E = 5
-(1/-2.367)
 = 1.97    E% = (1.97-1) x 100 = 97% 
BLyS:       E = 5
-(1/-2.390)
 = 1.96   E% = (1.96-1) x 100 = 96% 
IFNα:       E = 5-(1/-2.388) = 1.96   E% = (1.96-1) x 100 = 96% 
cDNA (ng) LOG Ct GAPDH St.Dev. Ct BLyS St.Dev. Ct IFNα St.Dev. 
100 2.861353     22.32 0.266     
20 1.861353 21.09 0.214 24.30 0.269 31.34 0.523 
4 0.861353 23.58 0.163 26.22 0.007 33.60 0.209 
0.8 -0.13865 26.22 0.176 29.46 0.148 36.06 0.126 
0.16 -1.13865 28.10 0.106     38.48 0.042 
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All efficiencies are similar and comprised between 95% and 105%. 
Efficiency curves performed with 200nM primers (data not shown) did not 
satisfy efficiency criteria. Real-time PCR performed afterwards were obtained 
using 100nM primers and 25ng cDNA. 
3.1.3 E2 treatment: BLyS gene expression 
U937 cells treated with E2 at different doses were evaluated for BLyS gene 
expression. BLyS mRNA was firstly evaluated in untreated cells at different 
time points. Cells used for seeding were considered as internal control, and 
relative fold change = 1 was attributed to them. There were no statistical 
differences in BLyS mRNA between U937 cells treated with vehicle EtOH 
0.01% during time, compared to cells at time zero (Table 3.2): vehicle 
(EtOH) treated cells could be considered as internal-time control for cells 
treated with E2 at scalar doses. No statistically significant BLyS mRNA 
modulation was observed at each time point and at each E2-dose 
administration (Figure 3.3). Also high E2 doses (100nM and 10nM) did not 
modulate gene expression within 48 hours. 
 U937 + EtOH 0.01% 
 BLyS Fold Change p 
6 hours 0.71 (0.39 – 1.28) n.s 
24 hours 0.99 (0.68 – 1.42) n.s 
48 hours 0.85 (0.54 – 1.34) n.s 
Table 3.2: Mean (min – max) BLyS fold change of U937 cells treated with EtOH 0.01% at 
different time points. U937 at time zero were considered as internal control with fold change 
equal to 1.  
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Figure 3.3: Mean (min-max) fold changes of BLyS mRNA expression in U937 cells after 6, 
24 and 48 hours of E2 treatment. Fold change = 1 was attributed, for each time point, to 
U937 cells treated with EtOH 0.01% (orange), considered as controls. 
3.1.4 E2 treatment: BLyS protein level 
Normalized BLyS protein levels (pg/µg total protein) in cell supernatants 
after E2 treatment is visualized in Figure 3.4. BLyS protein increased during 
time of treatment (FT), both in untreated and E2-treated cells. The dose of 
treatment poorly influences BLyS release in culture medium during time 
(FGxT). E2 treatment induced a significant increase in BLyS protein release at 
the highest doses (100nM and 10nM), while 1nM dose influenced in a 
negative way BLyS releasing by monocyte cells (FG).   
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Figure 3.4: Mean (± St.Dev.) BLyS protein release, normalized for total proteins, in U937 
monocytes after E2 treatment. The table shows the output of the multivariate analysis. FG = 
E2 treatment; FT = Time; FGxT = E2 treatment x Time. *p<0.05; **p<0.01; ***p≤0.001 
3.1.5 E2 treatment: IFNα gene expression 
E2 treatment did not induce BLyS mRNA modulation (paragraph 3.1.3), 
but it could be interesting to explore whether E2 could modulate IFNα mRNA 
within 48 hours. The RNA samples analyzed for BLyS mRNA were also 
evaluated for IFNα qPCR. First of all it was looked at IFNα expression by 
untreated cells during time (Table 3.3). 
 U937 + EtOH 0.01% 
 IFNα Fold Change p 
6 hours 0.61 (0.33 – 1.14) n.s. 
24 hours 0.80 (0.60 – 1.06) n.s. 
48 hours 0.16 (0.09 – 0.28) 0.001*** 
Table 3.3: Mean (min – max) IFNα fold change of U937 untreated cells at different time 
points. U937 at time zero were considered as internal control with fold change = 1.  
***p=0.001 
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After 48 hours, untreated cells showed a relevant statistically significant 
down-regulation of IFNα mRNA expression. E2 treatment induced IFNα up-
regulation at each dose and at each time point. The highest increase was 
noticed at 48 hours, where control cells expressed the lowest basal levels of 
target gene. The physiological E2 concentrations (1nM and 10nM) induced a 
time-dependent increase in IFNα mRNA expression. The other E2 
concentrations induced gene expression fluctuations during time, particularly 
at 24 hours, where it seemed to be a down-regulation of IFNα expression 
(Figure 3.5). 
 
Figure 3.5: Mean (min-max) fold changes of IFNα mRNA expression in U937 cells after 6, 
24 and 48 hours of E2 treatment. Fold change = 1 was attributed, for each time point, to 
U937 cells treated with EtOH 0.01% (purple), considered as controls. *p<0.05 **p<0.01 
***p<0.001 
3.1.6 hr-IFNα treatment: cell growth 
U937 cell growth was evaluated after hr-IFNα administration: starting 
from 48 hours, cell stopped dividing, and the difference with untreated cells 
was statistically significant (Figure 3.6). Cell growth retardation was not due 
to cell apoptosis, but to cell division arrest. 
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Figure 3.6: U937 cell density of untreated (red) and hr-IFNα-treated (violet) cells. Error bars 
represent standard deviations. *p<0.05 **p<0.01 
3.1.7 hr-IFNα treatment: BLyS gene expression 
IFNα treatment was performed to evaluate BLyS mRNA modulation. As in 
E2 treatment, U937 control cells (untreated), were considered as for basal 
BLyS gene expression at each time points (Table 3.4).  
 U937 
 BLyS Fold Change p 
6 hours 0.96 (0.77 – 1.20) n.s. 
10 hours 1.00 (0.82 – 1.23) n.s. 
24 hours 1.43 (1.32 – 1.56) 0.002** 
48 hours 1.35 (1.03 – 1.77) 0.004** 
Table 3.4: Mean (min – max) BLyS fold change of U937 untreated cells at different time points. 
U937 at time zero were considered as internal control with fold change = 1. **p<0.01 
Starting from 24 hours, untreated cells slightly increased BLyS mRNA 
expression, and the difference compared with time zero was statistically 
significant. 
hr-IFNα treatment induced moderate significant BLyS up-regulation 
starting from 10 hours, and the modulation is maintained during time (Figure 
3.7). 
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Figure 3.7: Mean (min-max) fold changes of BLyS mRNA expression in U937 cells after 6, 
10, 24 and 48 hours of hr-IFNα treatment. Fold change = 1 was attributed, for each time 
point, to U937 untreated cells (red), considered as controls.**p<0.01 ***p=0.001 
3.1.8 hr-IFNα treatment: BLyS protein level 
Normalized BLyS protein levels (pg/µg total protein) in cell supernatants 
after IFNα treatment is visualized in Figure 3.8. BLyS protein significantly 
accumulated during time of treatment (FT), both in untreated and IFNα-
treated cells. The dose of treatment did not influenced BLyS release in 
medium (FG), and the treatment did not modify significantly BLyS protein 
release during time (FGxT). 
 
Figure 3.8: Mean (± St.Dev.) BLyS protein release normalized for total proteins in U937 
monocytes after IFNα treatment. The table shows the output of the multivariate analysis. FG = 
hr-IFNα treatment; FT = Time; FGxT = hr-IFNα treatment x Time. ***p≤0.001 
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3.2 U937-derived macrophages 
3.2.1 PMA treatment: BLyS gene expression 
PMA induces cell differentiation from U937 monocytes to macrophage-
like cells. PMA treatment blocks cell proliferation, cells changed 
morphology, but do not increase in number. After medium replacement, 
macrophage-derived cells undergo apoptosis after 48-72 hours: qPCR 
experiments were performed within this time lapse. BLyS gene basal 
expression, after PMA differentiation, was not different from that of 
monocytic untreated cells (Figure 3.9). 
 
Figure 3.9: Mean (min – max) BLyS fold change of U937 untreated and PMA-treated cells. 
3.2.2 Primer efficiency curves 
Before evaluating target genes expression, primer’s efficiency was 
performed in U937-derived macrophages cell line. Table 3.5 shows mean Ct 
values of GAPDH, BLyS and IFNα genes for each cDNA dilution (from 
100ng to 0.16ng), using 100nM primer concentration. LOG represents the 
log(base5) of cDNA serial dilution. Extreme values, that did not interpolate in 
a good way the curve, were excluded. Figure 3.10 shows reference and target 
genes trends, with the corresponding linear regression equation and the 
coefficient of determination (R
2
). 
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ng LOG GAPDH St.Dev. BLyS St.Dev. IFNα St.Dev. 
100 2.861353     23.43 0.295     
20 1.861353 22.58 0.262 25.09 0.135 29.32 0.063 
4 0.861353 24.93 0.203 27.46 0.231 31.56 0.228 
0.8 -0.13865 27.34 0.007 30.23 0.194 33.80 0.211 
0.16 -1.13865 29.70 0.158     36.20 0.127 
Table 3.5: Ct mean values of GAPDH, BLyS and IFNα genes, for each cDNA dilution (from 
100ng to 0.16ng). Each sample was loaded in triplicate. St.Dev.=Standard Deviation. 
 
Figure 3.10: Efficiency curves of GAPDH (blue), BLyS (red) and IFNα (green) genes. For 
each gene linear regression is indicated. R
2
 = coefficient of determination. Ct = Threshold 
Cycle. LOG = log(base5) of cDNA quantity. 
Coefficient of determination values are near or equal to 1 and indicate that 
the line derived from points is similar to the line derived from linear 
regression. The efficiency for each gene is indicated in the expressions below. 
E is the efficiency, E% is the percentage of efficiency. 
GAPDH: E = 5
-(1/-2.377)
 = 1.97   E% = (1.97-1) x 100 = 97% 
BLyS:       E = 5
-(1/-2.277)
 = 2.03   E% = (2.03-1) x 100 = 103% 
IFNα:       E = 5-(1/-2.288) = 2.05   E% = (2.05-1) x 100 = 105% 
All primers efficiencies are included between 95% and 105%. Efficiency 
curves performed with 200nM primers (data not shown) did not satisfy 
efficiency criteria. Real-time PCR performed afterwards were obtained using 
100nM primers and 25ng cDNA, as in U937 monocytes. 
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3.2.3 E2 treatment: BLyS gene expression 
U937-derived macrophages treated with E2 at different doses were 
evaluated for BLyS gene expression. BLyS mRNA expression was firstly 
evaluated for untreated cells at different time points. Cells after 72 hours 
induction with PMA were considered as internal control, and relative fold 
change equal to 1 was attributed to them. There was no statistical difference 
between U937-derived macrophages treated with EtOH 0.01%  compared 
with cells at time zero (Table 3.6): EtOH-treated cells could be considered as 
internal-time control samples for cells treated with scalar concentrations of 
E2. No statistically significant BLyS mRNA modulation was found at each 
time point and at each E2-dose administration (Figure 3.11). At 6 hours, 1nM 
E2 induced a slight BLyS down-regulation, but p<0.05 value was not 
considered significant. Also high E2 doses (100nM and 10nM) did not 
modulate gene expression within 48 hours. 
 U937 + PMA + EtOH 0.01% 
 BLyS Fold Change p 
6 hours 0.63 (0.45 - 0.89) n.s. 
24 hours 0.97 (0.78 - 1.20) n.s. 
48 hours 0.82 (0.69 - 0.97) n.s. 
Table 3.6: Mean (min – max) BLyS fold change of U937-derived macrophages treated with 
EtOH 0.01% at different time points. U937 at time zero were considered as controls with fold 
change equal to 1. 
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Figure 3.11: Mean (min-max) fold changes of BLyS mRNA expression in U937-derived 
macrophages after 6, 24 and 48 hours of E2 treatment. Fold change = 1 was attributed, for 
each time point, to U937-derived macrophages treated with EtOH 0.01% (orange), 
considered as controls. *p<0.05. 
3.2.4 E2 treatment: BLyS protein level 
Normalized BLyS protein levels (pg/µg total protein) in U937-derived 
macrophage supernatants after E2 treatment is visualized in Figure 3.12. 
BLyS protein accumulated during time of treatment (FT), both in untreated 
and E2-treated cells. The dose of treatment poorly influenced BLyS release 
during time (FGxT). E2 treatment induced a significant increase in BLyS 
release starting from 1nM (FG). 
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Figure 3.12: Mean (± St.Dev.) BLyS protein release, normalized for total proteins, in U937-
derived macrophages after E2 treatment. The table shows the output of the multivariate 
statistical analysis. FG = E2 treatment; FT = Time; FGxT = E2 treatment x Time. *p<0.05; 
**p<0.01; ***p≤0.001 
3.2.5 E2 treatment: IFNα gene expression 
As for U937 monocytes, IFNα gene expression after E2 treatment was 
investigated. The same RNA samples of BLyS mRNA evaluation were used 
for IFNα qPCR. First of all, it was looked at IFNα expression by control cells 
during time (Table 3.7). 
 U937 + PMA + EtOH 0.01% 
 IFNα Fold Change p 
6 hours 1.25 (1.04 - 1.51) n.s. 
24 hours 2.30 (1.42 - 3.72) n.s. 
48 hours 1.61 (0.93 - 2.80) n.s. 
Table 3.7: Mean (min – max) IFNα fold change of untreated U937-derived macrophages at 
different time points. U937-derived macrophages after 72 hours PMA induction were 
considered as internal control with fold change = 1. 
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Untreated derived-macrophages did not showed any IFNα mRNA 
modulation during time. E2 treatment induced a statistically significant IFNα 
down-regulation at 24 hours for the doses 10nM and 100nM. Apart from the 
dosage 100nM, all the other E2 doses induced a time-dependent decrease of 
IFNα mRNA expression (Figure 3.13). 
 
Figure 3.13: Mean (min-max) fold changes of IFNα mRNA expression in U937-derived 
macrophages after 6, 24 and 48 hours of E2 treatment. Fold change = 1 was attributed, for 
each time point, to U937-derived macrophages treated with EtOH 0.01% (orange), 
considered as controls. *p<0.05 **p<0.01 
3.2.6 hr-IFNα treatment: U937-derived macrophages morphology 
During hr-IFNα treatment, U937-derived macrophages underwent 
apoptosis after 24 hours (Figure 3.14 B), confirming the in vitro IFNα anti-
proliferative effect. RNA samples derived from 24 and 48 hours were not 
affected in quantity and quality by this process. 
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3.2.7 hr-IFNα treatment: BLyS gene expression 
hr-IFNα treatment was performed to evaluate BLyS mRNA modulation in 
macrophage-derived cells. As in E2 treatment, untreated U937-derived 
macrophages were evaluated for basal BLyS gene expression at each time 
points (Table 3.8).  
 U937-derived macrophages 
 BLyS Fold Change p 
6 hours 0.57 (0.39 - 0.83) n.s. 
10 hours 1.67 (1.17 - 2.39) n.s. 
24 hours 0.69 (0.50 - 0.97) n.s. 
48 hours 0.58 (0.45 - 0.74) 0.029* 
Table 3.8: Mean (min – max) BLyS fold change of untreated U937-derived macrophages at 
different time points. U937-derived macrophages after 72 hours PMA-induction were 
considered as internal control with fold change = 1. *p<0.05 
At 48 hours, untreated cells slightly decreased BLyS mRNA expression. 
hr-IFNα treatment induced a highly significant BLyS up-regulation starting 
from 6 hours, then the up-regulation decreased, but it was maintained higher 
than controls during the observed time (Figure 3.15). 
A B Figure 3.14: Untreated (A) and hr-IFNα treated (B) U937-derived macrophages at phase 
contrast microscope. Magnification 200x. 
A B 
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Figure 3.15: Mean (min-max) fold changes of BLyS mRNA expression in U937-derived 
macrophages after 6, 10, 24 and 48 hours of hr-IFNα treatment. Fold change = 1 was 
attributed, for each time point, to untreated U937-derived macrophages (purple), considered 
as controls.**p<0.01 
3.2.8 hr-IFNα treatment: BLyS protein level 
Normalized BLyS protein levels (pg/µg total protein) in cell supernatants 
after IFNα treatment in U937-derived macrophages is visualized in Figure 
3.16. BLyS protein significantly accumulated during time of treatment (FT), 
both in untreated and IFNα-treated cells. The dose of treatment did not 
influenced BLyS release in medium (FG), but the treatment during time 
significantly decreased BLyS protein release (FGxT). 
 
Figure 3.16: Mean (± St.Dev.) BLyS protein release normalized for total proteins in U937-
derived macrophages after IFNα treatment. The table shows the output of the multivariate 
analysis. FG = hr-IFNα treatment; FT = Time; FGxT = hr-IFNα treatment x Time. **p<0.01; 
***p≤0.001  
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Hormones are important modulators of the immune response, and in 
autoimmune diseases, such as SLE, women are more affected than men, 
suggesting a pivotal role of estrogens in the pathogenesis of the disease. During 
pregnancy, the increase of estrogen levels induces a flare of the disease, and 
affects the production of pro- and anti-inflammatory cytokines: indeed, steroid 
hormone and cytokine profiles differ in SLE pregnant patients compared to 
healthy pregnant subjects [5,28,78]. In this study, it was evaluated the in vitro 
effects of E2 administration on BLyS and IFN expression in a human myeloid 
cell line, as a model of E2-induced effects on key cytokines in the pathogenesis of 
SLE and other B-cell mediated autoimmune diseases. 
The results suggest that in human U937 monocyte macrophage-like cells, a 
single pulse of E2 for 48 hours did not apparently affect BLyS gene expression, 
also at the highest E2 supra-physiological concentration used (100mM), even if 
some studies suggest that E2 is capable of inducing BLyS expression [18,79]. 
Very recently, it was reported that E2-induced BLyS up-regulation is higher in 
leukocytes derived from women than in leukocytes from men [79]. U937 as well 
as other monocytic cell lines, traditionally used as a model of macrophage 
function, derives from male myeloblastic tumor cells [80]. Otherwise, it has been 
established that U937 cells express both types of ERs, α and β, although their 
expression is different between monocytes and macrophages: ERα is prevalent in 
U937-derived macrophages, while ERβ is expressed mainly on U937 monocytes 
[81]. Of note, the timing of E2 treatment could influence BLyS expression: a work 
by Calippe et al. demonstrated that in vitro short-term  E2 administration in LPS-
activated macrophages does not predict the in vivo long-term effect of E2 in 
inducing mRNA expression of target cytokines [82]. Thus, these considerations 
could explain the discrepancy between the present study and literature data. 
Besides no apparent effects of E2 on BLyS gene expression and de-novo 
protein synthesis, in the present study it has been found that E2 at higher doses 
induces BLyS protein mobilization and release from both monocytes and PMA-
derived macrophages, as demonstrated by higher BLyS levels in supernatants 
from E2-treated cells. Even if BLyS protein level at highest E2 doses is 
significantly increased in treated than in untreated cells during time, the difference 
is not so evident. A recent study from our group indicated that the acute increase 
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of E2 during controlled ovarian stimulation for infertility treatment, does not 
induce a significant increase in BLyS circulating levels [83]. Conversely, in the 
experiments performed by Bassi et al. [12], the constant daily E2 administration 
increased BLyS protein levels in lupus-prone mice. These evidences regarding 
protein levels, in agreement with the findings by Calippe et al. [82] at 
transcription level, suggest that perhaps, a single pulse in vitro or a short-term in 
vivo E2 treatment protocol could be necessary but not sufficient to induce BLyS 
transcription, translation or mobilization. 
Regarding E2 effects on IFN gene expression, this study showed that E2 
treatment exerts an effect to some extent, which however seems apparently 
different in monocytes compared to macrophages, suggesting that E2 can evoke 
distinct gene responses in these two types of cells. E2-induced IFNα gene up-
regulation was confirmed in monocytes but not in derived macrophages. Looking 
again at the work by Mor et al., differences in ERs cell type distribution in 
monocytes and macrophages can induce different and opposite responses to E2 
treatment [81]. These findings could also be explained, at least in part, by the 
recent observation that estrogen-induced IFNα up-regulation in primary 
macrophages is reverted when estrogen is administered after virus infection [84]. 
Thus, in this in vitro model, PMA-induced differentiation before E2 treatment 
could probably reverse IFNα gene response.  
Since IFNα is modulated by E2, it was investigated whether exogenous IFNα 
administration could modulate BLyS gene and protein expression. As expected, it 
was found a strong BLyS gene up-regulation, higher in derived-macrophages than 
in monocytes, probably due to PMA differentiation. Panchanathan et al. also 
demonstrated the IFNα-induced up-regulation of BAFF in mouse macrophage 
cells [18]. Supporting this evidence, there are two other studies, in which 
exogenously or endogenously induced anti-IFNα antibodies can inhibit both BLyS 
transcription and protein release by blocking IFN signaling: anti-IFN drugs can 
neutralize over-expression of IFN-inducible genes, such as BLyS, in SLE patients 
[85,86]. Regarding BLyS protein release after IFNα treatment, these data are not 
in accordance with those of mRNA expression. BLyS is a trans-membrane protein 
that can become soluble only after specific furin-cleavage from cell surface. The 
work by Lopez et al., suggested that, in SLE patients, the release of BLyS from 
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primary monocytes after IFNα treatment, depends on patient’s anti-dsDNA titers 
and disease activity, suggesting that a peculiar cytokine milieu and/or cell 
activation could affect BLyS mobilization [74]. Probably, monocytes, and even 
more macrophages, are induced to express BLyS after IFNα induction, but they 
did not receive any particular stimuli able of promoting the cleavage of 
membrane-bound protein or the release of the intracellular one. 
Taken together all these findings suggest a possible pathway of E2-induced 
BLyS overexpression in myeloid cells, in which IFNα could be an essential 
mediator. Panchanathan et al. proposed that E2 and IFNα could independently 
induce BLyS by acting on a lupus susceptibility modifier protein, named p202, 
that is up-regulated both by ERα and IFNα [18]. However, this work did not take 
into account the well-known type I IFN gene activation by E2-ER signaling, that 
is also been recently described by Dong et al. [54]. Another recent paper by 
Gomez et al. [87], put in a causal relationship, in an ex vivo study, these three 
components, highlighting the role of IFNα in inducing BLyS in monocytes, and 
notably reporting that BLyS secretion has sex-related differences: monocytes 
from women produced higher basal BLyS levels compared with men, thus 
confirming a role for estrogen in determining BLyS secretion.  
Eventhough this work gives a contribution to elucidating estrogen 
immunomodulation, there are some limitations concerning the application of the 
same study design to primary monocyte-macrophage cells from sex-matched 
healthy subjects and SLE patients. Ex-vivo studies on primary peripheral cell 
populations could have better explained physiopathological response to E2 or 
IFN stimuli; however, a great heterogeneity related to primary cell culture 
assessment and patient’s clinical and treatment characteristics would have been 
expected. This work tried to propose a simple in vitro model of studying estrogen 
immunomodulatory effects on cytokine’s expression in human cell cultures, in 
order to approach the studies on primary cells in a more standardized and 
reproducible manner.  
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In conclusion, cytokines, such as IFNα and BLyS, are key modulators of innate 
and adaptive immune response, but such responses are exacerbated or attenuated 
by sex hormones, which have a pivotal role in controlling physiological 
immunity. In particular, sex hormones are implicated in the pathogenesis of B-cell 
mediated autoimmune diseases, including SLE. 
This study shows that E2 can modulate IFNα, and indirectly up-regulate BLyS 
gene expression, suggesting that estrogens could primarily have a role in the 
modulation of innate immunity, with different effects depending on target cell 
phenotype and milieu, as observed by comparing monocytes with derived-
macrophages. Estrogen effects on BLyS up-regulation are probably mediated by 
IFNα, cytokine of the innate immune response that enhances adaptive immune 
defenses. This study could represent a model of E2-induced adaptive immune 
response activation, thus confirming the interrelationship between innate and 
adaptive immunity in immune system modulation, and try to give a contribution 
to the elucidation of hormone-induced immune dysregulation in B-cell mediated- 
systemic autoimmunity. 
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